{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Colleoni M"],"funding":["NCI NIH HHS"],"pagination":["3400-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5035120"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["34(28)"],"pubmed_abstract":["Purpose
To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse effects in advanced breast cancer, in early breast cancer.Patients and methods
International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor- and progesterone receptor-negative (< 10% positive cells by immunohistochemistry) early breast cancer any nodal and human epidermal growth factor receptor 2 status, were randomly assigned anytime between primary surgery and 56 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamide 50 m"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00."],"pmcid":["PMC5035120"],"funding_grant_id":["U24 CA075362"],"pubmed_authors":["Gelber RD","Viale G","Gomez HL","Chirgwin J","Price KN","Eniu A","Rauch D","Kralidis E","Lang I","Puglisi F","Thurlimann B","Goldhirsch A","Linderholm BK","Tondini C","Colleoni M","Gray KP","Abdi EA","Coates AS","Gelber S","Regan MM","Gianni L","Cagossi K"],"additional_accession":[]},"is_claimable":false,"name":"Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.","description":"Purpose
To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse effects in advanced breast cancer, in early breast cancer.Patients and methods
International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor- and progesterone receptor-negative (< 10% positive cells by immunohistochemistry) early breast cancer any nodal and human epidermal growth factor receptor 2 status, were randomly assigned anytime between primary surgery and 56 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamide 50 m","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct","modification":"2026-05-01T20:43:22.128Z","creation":"2019-03-27T02:25:01Z"},"accession":"S-EPMC5035120","cross_references":{"pubmed":["27325862"],"doi":["10.1200/JCO.2015.65.6595","10.1200/jco.2015.65.6595"]}}